Clinical trial
In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus
NCT00354536 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00354536 |
|---|---|
| Title | In-patient Study With GSK716155 In Patients With Type 2 Diabetes Mellitus |
| Official title | A Single-blinded Randomized, Placebo-controlled, Staggered-parallel, Escalating-dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Injections of GSK 716155 in Subjects With Type 2 Diabetes Mellitus |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Biological, Drug |
| Interventions | GSK716155 subcutaneous injections, placebo injection |
| Enrollment | 60 |
| Start date | Feb 1, 2006 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Jul 20, 2006 |
| Last update posted | Oct 26, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: